Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy

Summary

We have shown that the thrombin G-protein coupled receptors (GPCR) designated as protease-activated receptors (PAR-1) are expressed in primary cancer cells isolated from peritoneal and pleural malignant effusions. Here, our main goal was to evaluate several coagulation and thrombin activation effectors and markers in a series of 136 malignant effusions from cancer patients with gastrointestinal, lung and mammary carcinomas. All these patients present a highly activated coagulation system in blood and their malignant effusions, as indicated by high levels of prothrombin F1.2 fragments and D-dimers. Notably, we detected in the effusions all the coagulation factors of the tissue factor pathway inducing thrombin activation, namely factorsVII, V, X and II, as well as high VEGF levels and IGF-II in mature and precursor forms. Fibrin clot formation also correlated with higher levels of free ionized calcium (iCa), suggesting that iCa and its binding protein albumin are regulatory factors for fibrinogenesis in effusions. Consequently, thrombin,VEGF and IGFII appear to converge in the promotion of survival and invasivity of the metastatic cancer cells from blood to the malignant effusions. Thus, we add new insights on the interconnections between blood coagulation disorders in cancer patients and thrombin activation in malignant effusions, including their functional interaction with PAR in metastatic cancer cells. Based on these data we propose to counteract the metastatic cascades by targeted invalidation of key effectors of the coagulation system. Therefore, potential therapeutic approaches include the application of thrombin protease inhibitors, VEGF-blocking antibodies, and drugs targeting the VEGF and thrombin signaling pathways, such as tyrosine kinase or GPCR inhibitors.

Keywords

Thrombin - PAR-1 - chemoresistance - invasion and survival

• References

• 1 Nguyen QD, De Wever O, Bruyneel E. et al Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment. Oncogene 2005; 24: 8240-8251.
• 2 van de Molengraft FJ, van 'tHof MA, Herman CJ. et al Quantitative light microscopy of atypical mesothelial cells and malignant cells in ascitic fluid. Anal Quant Cytol 1982; 4: 217-220.
• 3 Antunes G, Neville E. Management of malignant pleural effusions. Thorax 2000; 55: 981-983.
• 4 Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 1994; 120: 56-64.
• 5 Falanga A, Levine MN, Consonni R. et al The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trial. Thromb Haemost 1998; 79: 23-27.
• 6 Dirix LY, Salgado R, Weytjens R. et al Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86: 389-395.
• 7 Salgado R, Benoy I, Weytjens R. et al Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. Br J Cancer 2002; 87: 1437-1444.
• 8 Bromberg ME, Bailly MA, Konigsberg WH. Role of protease-activated receptor 1 in tumor metastasis promoted by tissue factor. Thromb Haemost 2001; 86: 1210-1214.
• 9 Even-Ram S, Uziely B, Cohen P. et al Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998; 4: 909-914.
• 10 Jenkins RG, Su X, Su G. et al Ligation of proteaseactivated receptor 1 enhances alpha(v)beta6 integrindependent TGF-beta activation and promotes acute lung injury. J Clin Invest 2006; 116: 1606-1614.
• 11 O'Brien PJ, Prevost N, Molino M. et al Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem 2000; 275: 13502-13509.
• 12 Prenzel N, Zwick E, Daub H. et al EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402: 884-888.
• 13 Feistritzer C, Lenta R, Riewald M. Protease-activated receptors-1 and –2 can mediate endothelial barrier protection: role in factor Xa signaling. J Thromb Haemost 2005; 3: 2798-2805.
• 14 Morris DR, Ding Y, Ricks TK. et al Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res 2006; 66: 307-314.
• 15 Ferguson JJ, Waly HM, Wilson JM. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition. Eur Heart J 1998; 19 (Suppl D) D3-9.
• 16 Andre F, Janssens B, Bruyneel E. et al Alpha-catenin is required for IGF-I-induced cellular migration but not invasion in human colonic cancer cells. Oncogene 2004; 23: 1177-1186.
• 17 Nguyen QD, Rodrigues S, Rodrigue CM. et al Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts. Mol Cancer Ther 2006; 5: 2070-2077.
• 18 Romeis B.. Mikroskopische Technik. ;17th ed. Urban, Schwarzenberg; Munich: 1989
• 19 Sarodia BD, Goldstein LS, Laskowski DM. et al Does pleural fluid pH change significantly at room temperature during the first hour following thoracentesis?. Chest 2000; 117: 1043-1048.
• 20 Grove CS, Lee YC. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med 2002; 8: 294-301.
• 21 Feng Y, Zhu Z, Xiao X. et al Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 2006; 5: 114-120.
• 22 Linnerth NM, Baldwin M, Campbell C. et al IGFII induces CREB phosphorylation and cell survival in human lung cancer cells. Oncogene 2005; 24: 7310-7319.
• 23 Min Y, Adachi Y, Yamamoto H. et al Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut 2005; 54: 591-600.
• 24 Richter AG, Maughan EO, Perkins GD. et al VEGF levels in pulmonary fibrosis. Thorax 2005; 60: 171.
• 25 Hamed EA, El-Noweihi AM, Mohamed AZ. et al Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions. Respirology 2004; 9: 81-86.
• 26 Das DK. Serous effusions in malignant lymphomas: a review. Diagn Cytopathol 2006; 34: 335-347.
• 27 Marchi E, Vargas FS, Acencio MM. et al Evidence that mesothelial cells regulate the acute inflammatory response in talc pleurodesis. Eur Respir J 2006; 28: 929-932.
• 28 Huang YQ, Li JJ, Hu L. et al Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. Thromb Haemost 2001; 86: 1094-1098.
• 29 Boire A, Covic L, Agarwal A. et al PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005; 120: 303-313.
• 30 Nguyen N, Kuliopulos A, Graham RA. et al Tumor-derived Cyr61(CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells. Cancer Res 2006; 66: 2658-2665.
• 31 Nguyen QD, Faivre S, Bruyneel E. et al RhoA- and RhoD-dependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion. Faseb J 2002; 16: 565-576.
• 32 Rak J, Klement P, Yu J. Genetic determinants of cancer coagulopathy, angiogenesis and disease progression. Vnitr Lek 2006; 52 (Suppl. 01) 135-138.
• 33 Regnauld K, Nguyen QD, Vakaet L. et al G-protein alpha(olf) subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells. Oncogene 2002; 21: 4020-4031.
• 34 Chen J, Bierhaus A, Schiekofer S. et al Tissue factor-- a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 2001; 86: 334-345.
• 35 Schiller H, Bartscht T, Arlt A. et al Thrombin as a survival factor for cancer cells: thrombin activation in malignant effusions in vivo and inhibition of idarubicin- induced cell death in vitro. Int J Clin Pharmacol Ther 2002; 40: 329-335.
• 36 Knowles H, Leek R, Harris AL. Macrophage infiltration and angiogenesis in human malignancy. Novartis Found Symp 2004; 256: 189-200. discussion –204, 259–269.
• 37 Robinson SC, Coussens LM. Soluble mediators of inflammation during tumor development. Adv Cancer Res 2005; 93: 159-187.
• 38 Rollins BJ. Inflammatory chemokines in cancer growth and progression. Eur J Cancer 2006; 42: 760-767.
• 39 Wang E, Panelli MC, Monsurro V. et al A global approach to tumor immunology. Cell Mol Immunol 2004; 1: 256-265.
• 40 Huang S, Van Arsdall M, Tedjarati S. et al Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002; 94: 1134-1142.
• 41 May KM, Vogt A, Bachas LG. et al Vascular endothelial growth factor as a biomarker for the early detection of cancer using a whole cell-based biosensor. Anal Bioanal Chem 2005; 382: 1010-1016.
• 42 Thickett DR, Armstrong L, Millar AB. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 1999; 54: 707-710.
• 43 Sriram PS, Mohammed KA, Nasreen N. et al Ad- herence of ovarian cancer cells induces pleural mesothelial cell (PMC) permeability. Oncol Res 2002; 13: 79-85.
• 44 Light RW. The undiagnosed pleural effusion. Clin Chest Med 2006; 27: 309-319.
• 45 Chu AJ. Tissue factor mediates inflammation. Arch Biochem Biophys 2005; 440: 123-132.
• 46 Bottles KD, Laszik Z, Morrissey JH. et al Tissue factor expression in mesothelial cells: induction both in vivo and in vitro. Am J Respir Cell Mol Biol 1997; 17: 164-172.
• 47 Versteeg HH. Tissue factor as an evolutionary conserved cytokine receptor: Implications for inflammation and signal transduction. Semin Hematol 2004; 41 (Suppl. 01) 168-172.
• 48 Chand HS, Ness SA, Kisiel W. Identification of a novel human tissue factor splice variant that is upregu upregulated in tumor cells. Int J Cancer 2006; 118: 1713-1720.
• 49 Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004; 2: 2065-2067.
• 50 Boulle N, Gicquel C, Logie A. et al Fibroblast growth factor-2 inhibits the maturation of pro-insulinlike growth factor-II (Pro-IGF-II) and the expression of insulin-like growth factor binding protein-2 (IGFBP-2) in the human adrenocortical tumor cell line NCIH295R. Endocrinology 2000; 141: 3127-3136.
• 51 Samani AA, Yakar S, Leroith D. et al The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28: 20-47.
• 52 Rak J, Milsom C, May L. et al Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 2006; 32: 54-70.
• 53 Nagy JA, Meyers MS, Masse EM. et al Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res 1995; 55: 369-375.
• 54 Green SK, Frankel A, Kerbel RS. Adhesion-dependent multicellular drug resistance. Anticancer Drug Des 1999; 14: 153-168.
• 55 Prevost GP, Lonchampt MO, Holbeck S. et al Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Galpha/Gbetagamma protein complex. Cancer Res 2006; 66: 9227-9234.